Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.

Mov Disord · 2019 · PMC6563183 · PMID 31002755

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Specifically, the ability of CaV1.3 silencing to reverse peak‐dose LIDs showed a nonsignificant trend of decreasing LID severity in the rAAV‐CaV1.3‐shRNA group (Fig. 2 B,C) compared with the rAAV‐Scr‐shRNA group beginning on day 20 postvector.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.